Insider Trading July 14, 2026 04:27 PM

HealthEquity Executive Michael Fiore Executes Pre-Planned Stock Sale Amid Analyst Optimism

EVP and CCO offloads shares via Rule 10b5-1 plan as institutional investors revise price targets upward following strong Q1 fiscal 2027 earnings.

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
HQY

Michael Henry Fiore, Executive Vice President and Chief Commercial Officer at HealthEquity, Inc. (NASDAQ: HQY), recently completed a stock transaction involving the sale of 2,354 shares on July 10, 2026. The transaction, valued at $223,630, was executed at a price of $95.00 per share. Following this disposition, Fiore retains direct ownership of 52,244 shares of the company’s common stock. The sale was carried out in accordance with a Rule 10b5-1 trading plan established by Fiore on October 14, 2025. This insider activity occurs as HealthEquity’s stock trades around $94.51, marking a 12% return over the preceding six months. Recent financial reporting for the first quarter of fiscal year 2027 has drawn positive attention from market analysts. The company reported earnings per share of $1.24, surpassing the expected $1.11, while revenue reached $354.6 million against a forecasted $351.87 million. In response to these results, RBC Capital reaffirmed its Outperform rating, citing confidence in growth and margin opportunities. Additionally, Citizens increased its price target to $111, revising fiscal 2027 non-GAAP EPS estimates to $4.70 and fiscal 2028 estimates to $5.46.

HealthEquity Executive Michael Fiore Executes Pre-Planned Stock Sale Amid Analyst Optimism
HQY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • HealthEquity Executive Michael Fiore sold 2,354 shares valued at $223,630 under a pre-existing Rule 10b5-1 plan adopted in October 2025.
  • Institutional investors RBC Capital and Citizens have revised their outlooks positively, with Citizens raising its price target to $111 and RBC reiterating an Outperform rating.
  • The company reported strong first quarter fiscal 2027 financial results, with EPS of $1.24 and revenue of $354.6 million, both exceeding market forecasts.

Michael Henry Fiore, serving as Executive Vice President and Chief Commercial Officer at HealthEquity, Inc. (NASDAQ: HQY), finalized a stock transaction on July 10, 2026. The executive sold 2,354 shares of the company's common stock, generating proceeds of $223,630. Each share was transacted at a price of $95.00. Post-transaction, Fiore maintains a direct holding of 52,244 shares in HealthEquity. The disposal was executed under a Rule 10b5-1 trading plan that Fiore adopted on October 14, 2025.

This insider activity takes place while HealthEquity's stock is trading near $94.51. The stock has recorded a 12% return over the past six months. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value. The company holds a financial health score of 3.64 out of 5, rated as "GREAT." The transaction occurred in the context of recent positive financial developments for the company. HealthEquity reported results for the first quarter of fiscal year 2027 that exceeded market expectations. The company posted earnings per share of $1.24, which was higher than the anticipated $1.11. The company also achieved revenue of $354.6 million, surpassing the forecasted $351.87 million. These results reflect strong performance and growth for the company.

In response to these developments, RBC Capital reiterated its Outperform rating for HealthEquity. The firm expressed increased confidence in the company's growth and margin opportunities. Meanwhile, Citizens raised its price target for HealthEquity shares to $111. The firm cited an improved margin outlook as the reason for the revision. Citizens also revised its fiscal 2027 non-GAAP earnings per share estimate to $4.70. The firm further revised its fiscal 2028 estimate to $5.46. These recent developments highlight the positive sentiment among analysts regarding HealthEquity's future prospects. The stock data indicates a closing price of 94.51, representing a decline of 1.15 or 1.20%. After hours trading showed a price of 95.00, an increase of 0.50 or 0.53%.

Risks

  • Insider selling by a key executive may be monitored by the market, though it was conducted under a pre-arranged trading plan.
  • HealthEquity's stock has shown recent volatility, closing at 94.51 with a 1.20% decline, indicating potential short-term price fluctuations.

More from Insider Trading

AppFolio Executive Maurice Duca Executes Pre-Arranged Stock Sales Amid Valuation Debate Jul 14, 2026 Planet Labs Director Raymond Executes Stock Sale Under Pre-Arranged Plan Jul 14, 2026 Netskope Director William Griffith Acquires $3.77 Million in Stock Jul 14, 2026 ICONIQ Strategic Partners VIII Acquires Netskope Shares Amid Mixed Analyst Outlook Jul 14, 2026 Analog Devices Director Golz Executes Pre-Arranged Stock Sale Jul 14, 2026